Zonisamide
Brand names: Zonisamide, Zonegran, Zonisade
At a glance
- Medicare prescriptions, 2024
- 307,475
- Medicare drug cost
- $20.3M
- Average cost per prescription
- $65.97
- Clinicians who prescribed it
- 9,252
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Neurology 54.3%
- Nurse Practitioners 17.4%
- Family Medicine 7.0%
- Internal Medicine 6.6%
- Physician Assistants 6.2%
- Pain Medicine 1.3%
- Psychiatry 1.2%
- Geriatric Medicine 0.9%
- Physical Medicine & Rehabilitation (PM&R) 0.7%
- Psychiatric Nurse Practitioners 0.7%
- Child Neurology 0.6%
- General Practice 0.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 8% from 2019 to 2024.
Biggest change by state since 2019
- Arkansas +30%
- Minnesota +17%
- Florida +15%
- Virginia +14%
- Kentucky +12%
- Mississippi (smallest change) −8%
- Tennessee (smallest change) −4%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Advanz Pharma (US) Corp.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | white capsule, 14 mm | ZONEGRAN 25 |
| 100 mg | red capsule, 19 mm | ZONEGRAN 100 |
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | brown capsule, 18 mm | IG 228 |
Cipla USA Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | brown capsule, 18 mm | IG 228 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | white capsule, 19 mm | ZA 33 100 MG |
Zydus Lifesciences Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | white capsule, 14 mm | ZA 31 25 MG |
| 50 mg | white capsule, 16 mm | ZA 32 50 MG |
| 100 mg | white capsule, 19 mm | ZA 33 100 MG |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $10,791 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Azurity Pharmaceuticals, Inc. $10,791
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Apr 2022 · Glenmark Pharmaceuticals Inc., USA · Class II
cGMP deviations - Aug 2021 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.